Authors
Latest:
Dr. Gwin on Potential Areas of Investigation With Alpha-TEA/Trastuzumab in Breast CancerWilliam R. Gwin III, MD, discusses potential areas of investigation with the combination of alpha-tocopheryloxyacetic acid (alpha-TEA) and trastuzumab (Herceptin) in breast cancer.
Latest:
Dr. Jarnagin on Surgical Protocols for CRC That Have Spread Beyond the LiverWilliam R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the surgical barriers in treating patients with colorectal cancer that has metastasized outside of the liver.
Latest:
Dr. Jarnagin on the Improvements in Surgery for Patients With mCRCWilliam R. Jarnagin, MD, FACS, chief, Hepatopancreatobiliary Service, Benno C. Schmidt Chair, Surgical Oncology, Memorial Sloan Kettering Cancer Center, discusses the progression of surgery in treating patients with metastatic colorectal cancer.
Latest:
Palliative Care Issues in Gynecologic CancerPalliative care should address the unique symptom profile of gynecologic cancer and be tailored to individual socioeconomic environments.
Latest:
Dr. DeRosa Discusses Nab-Paclitacel in Lung CancerWilliam T. DeRosa, DO, from Carol G. Simon Cancer Center at Morristown Memorial Hospital, discusses subset analyses from the phase III CA031 trial that examined nab-paclitaxel in non-small cell lung cancer.
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment RecommendationsResearchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Latest:
Individualized Approach to Treatment for the Elderly Ovarian Cancer PatientStuart Lichtman, MD, and William Tew, MD, from Memorial Sloan-Kettering Cancer Center, discuss personalizing treatment for elderly patients with ovarian cancer.
Latest:
Smartphones Moving to the Front Line of Mobile Technology for PhysiciansTraditionally, physicians have relied on textbooks, conferences, and, more recently, the Internet to keep abreast of the latest clinical data and support clinical decision-making
Latest:
CLL: Final ThoughtsAn expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
Latest:
Novel Proteasome Inhibitors for Multiple MyelomaMultiple new proteasome inhibitors currently in clinical or preclinical development bode well for potential future therapies for multiple myeloma, both in frontline and relapsed or refractory settings.
Latest:
Dr. Gerritsen on a Study of Alisertib in Neuroendocrine Prostate CancerWinald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the activity of alisertib monotherapy in patients with neuroendocrine prostate cancer.
Latest:
Dr. Tan on Imaging Modalities in Prostate CancerWinston Tan, MD, hematologist/oncologist, Mayo Clinic, discusses imaging modalities in prostate cancer.
Latest:
Dr. Wojciech Jurczak on MOR208 in Non-Hodgkin's LymphomaWojciech Jurczak, MD Head of Lymphoma, Department of Hematology, Jagiellonian University, Kopernika, Poland, discuses a subgroup analyses of diffuse large b-cell lymphoma (DLBCL) and indolent lymphoma cohorts from a phase IIa study of single-agent MOR208 in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL).
Latest:
Dr. Fendler on Impact of 68Ga-PSMA-11 PET on Prostate Cancer ManagementWolfgang Fendler, MD, discusses the utility and pending FDA approval of 68Ga-PSMA-11 PET in prostate cancer.
Latest:
Dr. Hiddemann on Updated Results of Immunochemotherapy Study in Follicular LymphomaWolfgang Hiddemann, MD, PhD, director of the Department of Hematology and Oncology, University of Munich, discusses the updated results of an immunochemotherapy study in follicular lymphoma.
Latest:
Dr. Janni on the Influence of Biosimilars in OncologyWolfgang Janni, MD, PhD, professor and chair of the Department of Obstetrics and Gynecology at the University of Ulm, Germany, discusses the influence of biosimilars in oncology.
Latest:
Dr. Bosch Discusses the Importance of the HPV VaccineXavier Bosch, MD, MPH, Unit of Infections and Cancer (UNIC), Cancer Epidemiology Research Programme, Institut Catala d' Oncologia–Catalan Institute of Oncology, discusses the importance of the HPV vaccine in the prevention of cervical cancer.
Latest:
Dr. Wei on Immune-Related Adverse Events in GU CancersXiao X. Wei, MD, MAS, instructor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses immune-related adverse events (irAE) in genitourinary (GU) cancers.
Latest:
Daily and Cumulative Dose Recalculation and in Vivo Verification for Helical TomoTherapy: Multicenter ValidationRapid advances in the technological development of precise and conformal radiation therapy and its incorporation into the clinic have generally outpaced our ability to test these technologies in a clinical trial format.
Latest:
Dr. Meng on MRI-US Fusion Targeted Biopsy for High-Grade Prostate CancerXiaosong Meng, MD, PhD, NYU Langone Medical Center, discusses MRI-US fusion targeted biopsies and how they can be used to identify high-grade prostate cancers.
Latest:
Dr. Xifeng Wu on Prognostic Factor of Obesity-Related Genes in RCCXifeng Wu, MD, PhD, chair, Department of Epidemiology, Division of OVP, Cancer Prevention and Population Sciences, director, Center for Translational and Public Health Genomics, professor, The University of Texas MD Anderson Cancer Center, discusses the prognostic factor of obesity-related genes in patients with renal cell carcinoma (RCC).
Latest:
Phase II Clinical Trial of Intratumoral Dendritic Cells Injections and Neoadjuvant Radiotherapy in Resectable Soft Tissue SarcomasNeoadjuvant radiation with dendritic cell injections has the potential to be safe, effective, and immunogenic in high-grade soft tissue sarcoma and needs to be confirmed in randomized larger clinical trials.
Latest:
Emerging CAR T-Cell Therapies in Hematologic CancersXiuli Wang, PhD, discusses emerging CAR T-cell therapy in hematologic cancers.
Latest:
Dr Le on the Efficacy of Osimertinib Plus Ramucirumab in EGFR-Mutant mNSCLCXiuning Le, MD, PhD, discusses findings from the interim analysis of the phase 2 RAMOSE trial in patients with TKI-naïve metastatic non–small cell lung cancer harboring EGFR mutations.
